Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $1,946,479.28 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Exelixis Stock Up 1.7 %

NASDAQ EXEL opened at $37.53 on Thursday. The company has a market cap of $10.50 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $37.64. The business’s fifty day moving average is $34.34 and its 200 day moving average is $31.50.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Citigroup upped their price objective on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and lifted their target price for the company from $36.00 to $40.00 in a research report on Friday, December 20th. Piper Sandler upped their price target on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Finally, StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and an average price target of $37.24.

Institutional Investors Weigh In On Exelixis

Several hedge funds have recently added to or reduced their stakes in EXEL. Coppell Advisory Solutions LLC acquired a new position in Exelixis in the 4th quarter valued at approximately $25,000. Colonial Trust Co SC grew its stake in shares of Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 765 shares during the last quarter. Principal Securities Inc. grew its stake in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the last quarter. USA Financial Formulas acquired a new stake in Exelixis in the fourth quarter valued at $32,000. Finally, Kestra Investment Management LLC bought a new position in Exelixis during the 4th quarter worth $39,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.